Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogeni… Read more
Theravance Biopharma Inc (TBPH) - Total Liabilities
Latest total liabilities as of September 2025: $182.78 Million USD
Based on the latest financial reports, Theravance Biopharma Inc (TBPH) has total liabilities worth $182.78 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Theravance Biopharma Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Theravance Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Theravance Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of Theravance Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
STEF S.A
LSE:0NY3
|
UK | €2.84 Billion |
|
Shoei Co Ltd
PINK:SHOFF
|
USA | $4.52 Billion |
|
Cembre S.p.A.
F:J0L
|
Germany | €72.67 Million |
|
Guangdong Lyric Robot Automation Co Ltd
SHG:688499
|
China | CN¥5.84 Billion |
|
China Aviation Oil (Singapore) Corporation Ltd
F:VZ8
|
Germany | €1.19 Billion |
|
POTBELLY - Frankfurt Stock Exchang
F:PTB
|
Germany | €204.14 Million |
|
Fulgent Genetics Inc
NASDAQ:FLGT
|
USA | $93.81 Million |
|
YIFILASER ORD A (SHH) EQSW Exp:
SHG:688646
|
China | CN¥1.25 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Theravance Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Theravance Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Theravance Biopharma Inc (2011–2024)
The table below shows the annual total liabilities of Theravance Biopharma Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $178.62 Million | +5.69% |
| 2023-12-31 | $169.00 Million | +2.06% |
| 2022-12-31 | $165.60 Million | -76.79% |
| 2021-12-31 | $713.39 Million | -7.69% |
| 2020-12-31 | $772.81 Million | +22.15% |
| 2019-12-31 | $632.67 Million | +3.41% |
| 2018-12-31 | $611.82 Million | +87.55% |
| 2017-12-31 | $326.22 Million | +12.87% |
| 2016-12-31 | $289.02 Million | +406.60% |
| 2015-12-31 | $57.05 Million | +18.90% |
| 2014-12-31 | $47.98 Million | +13.67% |
| 2013-12-31 | $42.21 Million | +86.19% |
| 2012-12-31 | $22.67 Million | -85.33% |
| 2011-12-31 | $154.54 Million | -- |